Axovant Gene Therapies Ltd. (NASDAQ: AXGT) was founded in 2014, formerly known as Axovant Sciences Ltd. (formerly NASDAQ: AXON), Axovant gene therapy company Axovant Gene Therapies Ltd. (formerly NASDAQ: AXON). In December 2018, it obtained 2 treatments for GM1 Ganglioside and Tay -Sachs and Sandhoff’s gene therapy products were changed to their current names. The company name was Roivant Neurosciences Ltd. before, and it was changed to Axovant Sciences Ltd. in March 2015. Headquartered in London, UK, it has 38 full-time employees. A clinical-stage gene therapy company dedicated to developing a series of candidate products for alleviating neurological and neuromuscular diseases.
Axovant Gene Therapies Ltd. (AXGT):
Axovant Gene Therapies’ current gene therapy drug candidates target GM1 gangliosidosis, GM2 gangliosidosis, Parkinson’s disease, ophthalmopharyngeal muscular dystrophy, amyotrophic lateral sclerosis and frontotemporal dementia.
- In June 2018, the company obtained the global rights to AXO-Lenti-PD from Oxford BioMedica, which is a gene therapy for the treatment of Parkinson’s disease.
- In July 2018, the company obtained the rights to AXO-AAV-OPMD from Benitec Biopharma , an investigational gene therapy for ophthalmopharyngeal muscular dystrophy.
Axovant Gene Therapies Ltd., like Myovant Sciences Ltd. , Urovant Sciences Ltd. and Dermavant Sciences Ltd. , are all listed subsidiaries of Roivant Sciences Ltd. in the UK .
Former Axovant Sciences:
The original Axovant Sciences focused on the research and development of innovative therapies for neurodegenerative diseases (such as Alzheimer’s disease), and was committed to becoming a leading biopharmaceutical company. The company’s main product candidate RVT-101 is used to treat Alzheimer’s disease and other forms of dementia. The product was acquired from GlaxoSmithKline in December 2014. The company began to treat RVT in the fourth quarter of 2015. -101 is undergoing phase III clinical trials for the treatment of mild to moderate Alzheimer’s disease. In the long run, it intends to develop a full-product assembly line to comprehensively address the cognition, behavior and function of patients with Alzheimer’s disease.
On September 25, 2017, Axovant Sciences stated that its experimental Alzheimer’s disease drug failed to meet the key trial target, and its stock price plummeted 73%.
Axovant Gene Therapies Ltd. (AXGT) investment:
Axovant Sciences Ltd. submitted its prospectus on May 11, 2015, and listed on the New York Stock Exchange on 6/11/2015 with an issue price of US$15. It issued 21 million shares and raised US$315 million. The stock code is AXON.